openPR Logo
Press release

Sexually Transmitted Diseases (STDs) Drug Market to Expand with a CAGR of 11.2% due to 2025

02-05-2019 07:14 PM CET | Health & Medicine

Press release from: Transparency Market Research

Sexually Transmitted Diseases (STDs) Drug Market to Expand with

Global Sexually Transmitted Diseases Drug Market:

Sexually transmitted diseases (STDs), also referred as venereal diseases are infections that can pass from person to person during sex. These diseases are caused mainly due to bacteria, viruses, and / or parasites. Sexually transmitted diseases (STDs) often go undiagnosed because these infections usually do not exhibit visual symptoms. Changes in urination, Pain during sex, unusual discharge from the penis, abnormal vaginal discharge or bleeding, bumps or sores, pain in the pelvic or abdominal region, burning or itching in the vaginal area are most common symptoms for sexually transmitted diseases (STDs).

Read Report Overview @ https://www.transparencymarketresearch.com/sexually-transmitted-disease-drugs-market.html

These all symptoms help to diagnose sexually transmitted diseases (STDs). Nucleic Acid Amplification Tests (NAAT), direct fluorescent tests and others test recommended by healthcare specialist to confirm sexually transmitted diseases (STDs). Chlamydia, gonorrhea, HIV/AIDS, Human papillomavirus infection and syphilis are the most common types of sexually transmitted diseases (STDs. As per WHO 2015 report, near about 1.1 billion people had sexually transmitted diseases (STDs) other than HIV/AIDS. About 500 million people were infected with either chlamydia, gonorrhea syphilis or trichomoniasis. At least 250 million women suffering from human papillomavirus while 530 million case find with genital herpes.
sexually transmitted diseases

Request Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34043

Hospital Segment to Turn Lucrative, Fuelling Demand for Sexually Transmitted Disease Drugs

The global market for sexually transmitted diseases (STDs) drug is expanding significantly, owing to increased chances of infection led by increase in the life expectancy of people across the globe. Rise in incidences of unprotected sex has led to an increase in the prevalence of sexually transmitted diseases. A driving factor for the sexually transmitted diseases (STDs) drug is rising initiatives by governments and multiple agencies drawn up guidelines or recommendations for sexually transmitted diseases (STDs). Low voluntary screening rate for sexually transmitted diseases (STDs) is major restrain for this market.

The global sexually transmitted diseases (STDs) drug market can be segmented on the basis of disease type, therapy class, distribution channel, and region. On the bases of disease type, sexually transmitted diseases (STDs) drug market can be further segmented into chlamydia, gonorrhea, syphilis, human papillomavirus infection, HIV/AIDS and others.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=34043

According to therapy class sexually transmitted diseases (STDs) drug market can be segmented into antibiotics, antiviral, vaccines and others. In terms of distribution channel, the sexually transmitted diseases (STDs) drug market can be segmented into hospitals pharmacies, retail pharmacies, online pharmacies and others. In terms of revenue, the hospitals segment held a significant share of the sexually transmitted diseases (STDs) drug market in 2016.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: roshan.k@tmr.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sexually Transmitted Diseases (STDs) Drug Market to Expand with a CAGR of 11.2% due to 2025 here

News-ID: 1562473 • Views:

More Releases from Transparency Market Research

Neuromorphic Chip Market to Reach USD 2.3 Billion by 2034, Driven by Explosive AI Adoption and Next-Generation Edge Computing Innovations | TMR
Neuromorphic Chip Market to Reach USD 2.3 Billion by 2034, Driven by Explosive A …
The global Neuromorphic Chip Market is entering a defining phase of exponential growth, propelled by a surge in artificial intelligence (AI) applications, edge computing expansion, and rapid advancements in next-generation semiconductor technologies. According to the latest industry analysis, the market-valued at US$ 56.2 Mn in 2023-is projected to expand at an extraordinary CAGR of 40.1% from 2024 to 2034, reaching an estimated US$ 2.3 Bn by 2034. Examine key highlights and
Neuroprotection Market Surges Toward USD 60.1 Bn by 2031 as Global Neurological Disease Burden Accelerates | TMR
Neuroprotection Market Surges Toward USD 60.1 Bn by 2031 as Global Neurological …
The global Neuroprotection Market continues to gain unprecedented momentum as healthcare systems worldwide intensify their focus on combating neurological disorders. With a valuation of US$ 31.6 Bn in 2022, the market is on track to reach US$ 60.1 Bn by 2031, expanding at a robust 7.5% CAGR during the forecast period. The rise in dementia, stroke, Parkinson's, epilepsy, and multiple sclerosis-combined with aging demographics and a surge in sedentary lifestyles-has
Neuroregeneration Therapy Market Set to Reach USD 64.8 Bn by 2034, Driven by Innovations in Gene Editing, Stem Cell Therapy, and AI-Based Neuromedicine | TMR
Neuroregeneration Therapy Market Set to Reach USD 64.8 Bn by 2034, Driven by Inn …
The global neuroregeneration therapy market continues to chart steady, sustained growth. The increasing incidence of neurological disorders-including Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, stroke, diabetic neuropathy, and spinal cord injuries-is significantly influencing market expansion. In 2023, the market was worth US$ 37.0 Bn, demonstrating rising demand for treatments capable of repairing or regenerating damaged neural tissue. Examine key highlights and takeaways from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86322 With breakthroughs
Neuroscience Market Set to Reach USD 41.6 Bn by 2031 Driven by Technological Advances in Brain Mapping, AI, and Portable Neuroimaging | TMR
Neuroscience Market Set to Reach USD 41.6 Bn by 2031 Driven by Technological Adv …
The global neuroscience market stood at US$ 30.1 Bn in 2022, reflecting the significant technological and clinical potential of neurological research. Projected to grow at a CAGR of 3.7% from 2023 to 2031, the industry is expected to reach US$ 41.6 Bn by 2031. Rising prevalence of neurodegenerative diseases, advancements in neuroimaging, integration of artificial intelligence, and the emergence of brain-computer interfaces are shaping the next decade of neuroscience innovation. Examine

All 5 Releases


More Releases for STDs

Diagnostic Testing of STDs Market Predicted Double-Digit Growth Rate by 2028
Diagnostic Testing of STDs Market Research study which offers perceptivity of in- depth delving on major and current request size along with the expected future prospects of the request and arising trends in the request. The Diagnostic Testing of STDs Market report provides crucial information about the request, including Opinions from diligence experts, and accordingly the recent progressions and developments of the Diagnostic Testing of STDs Market. The report contains documentary
Influence of Covid-19 on Sexually Transmitted Diseases (STDs) Drug Market
Transparency Market Research (TMR) observes, the global sexually transmitted diseases (STDs) drug market is highly competitive due to presence of several strong players. The key players are investing on the research and development activities for developing a novel drugs in order to be a part of competition. Some of the key players in the global sexually transmitted diseases drug market includes Pfizer INC, Bayer Healthcare, Hoffmann La Roche, Eli Lilly,
STDs Diagnosis Market : Industry Growth, Size, Manufacturers, Sales and Demand
ReportsnReports recently announces a latest research report titled “Global STDs Diagnosis Market 2018” which highlights the STDs Diagnosis Market size, comprehensive STDs Diagnosis Industry dynamics and high-tech updates of global STDs Diagnosis Market with respect to STDs Diagnosis Industry opportunities, threats, challenges, constraints, cost structure and current trends in the STDs Diagnosis Industry. This independent 116 Page report based on analysis over 6 Major Key Players guarantees you will remain
Sexually Transmitted Diseases (STDs) Treatment Market Outlook and Opportunity An …
Sexually transmitted disease also known as venereal diseases is a clinical syndrome of infection, acquired and transmitted through sexual activity via body fluids such as semen, vaginal fluid or blood. Causative agent of STD are bacteria, parasites, yeast, and viruses. Symptoms of STDs includes skin rashes, warts, abdominal pain or genital ulcers. STDs are detected by physical examination or assays such as ELISA (Enzyme Linked Immunosorbent Assay), rapid plasma reagin
Sexually Transmitted Diseases (STDs) Treatment Market Opportunity Analysis, 2018 …
Sexually transmitted disease also known as venereal diseases is a clinical syndrome of infection, acquired and transmitted through sexual activity via body fluids such as semen, vaginal fluid or blood. Causative agent of STD are bacteria, parasites, yeast, and viruses. Symptoms of STDs includes skin rashes, warts, abdominal pain or genital ulcers. STDs are detected by physical examination or assays such as ELISA (Enzyme Linked Immunosorbent Assay), rapid plasma reagin
Global Diagnostic Testing of STDs Market to Reach US$108.5 bn by 2019, Propelled …
Transparency Market Research has published a new report on the global diagnostic testing of STDs market. As per the report, the global diagnostic testing of STDs market is expected to expand at an 8.10% CAGR during the period from 2013 to 2019. The report, titled ‘Diagnostic Testing of STDs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019’, states that the global diagnostic testing of